A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (NCT05889182)

The M23-698 trial is a study designed to evaluate the safety and efficacy of a potential new medication compared to placebo in reducing symptoms and improving the quality of life for participants living with Hidradenitis Supparativa (HS). Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both administered as oral treatments. The study will involve 19 study visits over the course of approximately two years.  

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Professor Johannes S Kern

Key inclusion data

Are 18 years or older
Have been diagnosed with HS for at least 6 months
Have not seen improvement from a previous HS treatment